Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Short Interest Update

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 129,700 shares, an increase of 118.4% from the May 15th total of 59,400 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 143,300 shares, the days-to-cover ratio is currently 0.9 days.

Shionogi & Co., Ltd. Stock Performance

Shares of SGIOY traded up $0.01 during midday trading on Friday, hitting $8.55. 132,148 shares of the stock traded hands, compared to its average volume of 113,331. Shionogi & Co., Ltd. has a 1-year low of $6.22 and a 1-year high of $8.97. The firm has a market capitalization of $14.55 billion, a PE ratio of 14.40, a price-to-earnings-growth ratio of 2.37 and a beta of 0.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.01 and a current ratio of 7.64. The business’s 50 day moving average price is $8.15 and its two-hundred day moving average price is $7.58.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.03). Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 12.02%. The firm had revenue of $721.77 million for the quarter, compared to analyst estimates of $824.23 million. Equities research analysts predict that Shionogi & Co., Ltd. will post 0.66 EPS for the current fiscal year.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.